Pembrolizumab/Ipilimumab combo data | PVCT Message Board Posts

Provectus Biopharmaceuticals, Inc.

  PVCT website

PVCT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  31822 of 40141  at  6/16/2016 4:26:51 PM  by

canis_star


Pembrolizumab/Ipilimumab combo data

 Of the total study population (n = 153), the ORR was 57% (95% CI, 49%-65%) according to RECIST v1.1, independent central review. The disease control rate, or the rate of complete responses, partial responses (PR), and stable diseases (SD), was 78% (95% CI, 71%-85%). Overall, 15 patients (10%) had CR, 72 (47%) had PR, 33 (22%) had SD, and 30 (20%) had progressive disease. Post-baseline scans were not performed on 3 of the patients (2%). - See more at: http://www.targetedonc.com/conference/asco-melanoma-2016/pembrolizumabipilimumab-combo-is-safe-in-advanced-melanoma#sthash.drD8Hw4D.O0ITZW6j.dpuf


http://www.targetedonc.com/conference/asco-melanoma-2016/pembrolizumabipilimumab-combo-is-safe-in-advanced-melanoma
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 304
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
31832 Re: Pembrolizumab/Ipilimumab combo data hankenb 2 6/16/2016 8:55:42 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...